She Completed An Internal Medicine Intern Ship At St.

downer BC, Mae R, Becket MD, Heinz C, Veltrup I, Heiligenhaus A, Barisani-Asenbauer T, Mackensen F. Thiagarajan G, Chandani S, Harinarayana Mao S, et al. Uveitis can cause permanent damage to the eyes and vision loss that cannot be reversed. mosey; 2008. Another form of uveitis is pars planitis. The word “intermediate” in the name refers to the location of the inflammation and not the severity of the inflammation. Parekh A, et al. HLA-B27 AA has characteristic clinical features including male preponderance, unilateral alternating acute onset, a non-granulomatous appearance, and frequent recurrences whereas HLA-B27 negative AA has an equivalent male to female onset, bilateral chronic course, and more frequent granulomatous appearance. 7 Rheumatoid arthritis is not uncommon in Asian countries as a significant association of uveitis. 8 non-infectious or autoimmune causes edit Onset of uveitis can broadly be described as a failure of the ocular immune system and the disease results from inflammation and tissue destruction. She completed an internal medicine intern ship at St. Conventional treatment produced few side effects. She received her BA from Pomona College in Claremont, A, and her MD from the University of Colorado in Denver, CO. s editorial policy, editorial process and privacy policy.

This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. no dataPhil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Ideras proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com . Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements about potential treatments for cancer or other diseases employing combinations of drug therapies including Ideras third generation gene silencing technology. The Other Remedies Are: Take Plenty Of Rest, Keep Yourself Well-hydrated, And Take Hot Baths Or Steam. » Jeremiah Shaw CodeSuch statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on the companys current beliefs and expectations.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

Leave a Reply

Your email address will not be published. Required fields are marked *